Wellington-Altus USA’s Biogen BIIB Stock Holding History

Wellington-Altus USA’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,219	Closed	-$263K	–	662
2026 Q1	$263K	Buy	+1,219	New	+$225K	0.16%	131

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington-Altus USA's BIIB Position: Q2 2026 in Review

Wellington-Altus USA sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,219 shares — an estimated $263K sold.

Wellington-Altus USA first reported a position in BIIB in Q1 2026 and held it in 1 quarter. The position peaked at $263K in Q1 2026. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Wellington-Altus USA reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Wellington-Altus USA sold 1,219 Biogen shares in Q2 2026, an estimated $263K.
Wellington-Altus USA first reported a position in Biogen in Q1 2026 and held it in 1 quarter.
Wellington-Altus USA's Biogen position peaked at $263K in Q1 2026.
1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Wellington-Altus USA's 13F filing for Q2 2026, filed 17 Sep 2026.